Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF
- Design
- Animal study
- Drugs
- Semaglutide
- Assessment
- Not yet reviewed by a person · added Oct 11, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved. This item has not been peer reviewed.
01Source
The source, as retrieved
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events in patients with type 2 diabetes and obesity[1, 2], but the mechanisms underlying these benefits remain incompletely defined. Although GLP-1RAs improve vascular function[3] and alter circulating lipid species associated with cardiovascular risk [4-6], whether these effects extend to diseased coronary vessels and occur independently of weight loss is unknown. Here, we show that weight-neutral semaglutide administration in two complementary cardiometabolic HFpEF models - a porcine model of metabolic syndrome with coronary artery disease and the ZSF-1 obese HFpEF rat - improves coronary and aortic endothelium-dependent vasodilation, attenuates coronary vascular remodeling and fibrosis, increases myocardial microvascular density, and remodels the plasma lipidome through reductions in ceramides and diacylglycerols together with enrichment of long-chain polyunsaturated triacylglycerols. These findings identify direct vascular and metabolic actions of semaglutide that are independent of weight loss.